Elfriede Bollschweiler
YOU?
Author Swipe
View article: Premature mortality for patients after completely resected early adenocarcinoma of the esophagus or stomach
Premature mortality for patients after completely resected early adenocarcinoma of the esophagus or stomach Open
Objective To establish the life expectancy burden of esophago‐gastric cancer by analyzing years of life lost (YLL) for a Western patient population after treatment of early esophageal (EAC) or early gastric (GAC) adenocarcinoma. Background…
View article: Surgical approach to advanced Siewert II cancer: beyond the borders? The West Side
Surgical approach to advanced Siewert II cancer: beyond the borders? The West Side Open
View article: Does VO<sub>2</sub>peak Provide a Prognostic Value in Esophagectomy and Gastrectomy for Post-operative Outcomes?
Does VO<sub>2</sub>peak Provide a Prognostic Value in Esophagectomy and Gastrectomy for Post-operative Outcomes? Open
The impaired functional capacity following esophagectomy or gastrectomy may strengthen the rational for exercise programs during neoadjuvant and pre-surgery phases. The prognostic value of VO2peak on post-operative outcomes rema…
View article: Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by <i>ERCC1</i> or <i>ABCB1</i>
Different response rates to chemotherapy between Japanese and German esophageal squamous cell carcinoma: patients may be influenced by <i>ERCC1</i> or <i>ABCB1</i> Open
Aim: To find out differences in biomarkers between Japanese and German patients responsible for response after neoadjuvant radio/chemotherapy and survival for esophageal squamous cell carcinoma. Materials & methods: A total o…
View article: Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients
Neoadjuvant chemoradiation changes podoplanin expression in esophageal cancer patients Open
Analysis of the molecular process that leads to decrease in podoplanin expression during neoadjuvant treatment and its regulation may provide novel markers and targets to improve targeted therapy of ESCC.
View article: External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer Open
View article: Prognostic relevance of tumor response after neoadjuvant therapy for patients with esophageal cancer
Prognostic relevance of tumor response after neoadjuvant therapy for patients with esophageal cancer Open
In recent years, pre and perioperative chemotherapy or chemoradiotherapy have been successfully implemented for advanced esophageal carcinoma (1,2). Traditionally, the resected specimen and lymph nodes (LN) have been evaluated according to…
View article: Upregulation of miR-17-92 cluster is associated with progression and lymph node metastasis in oesophageal adenocarcinoma
Upregulation of miR-17-92 cluster is associated with progression and lymph node metastasis in oesophageal adenocarcinoma Open
View article: Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence Open
View article: Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus
Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus Open
View article: Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study
Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study Open
View article: High protein and mRNA expression levels of TUBB3 (class III ß-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas
High protein and mRNA expression levels of TUBB3 (class III ß-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas Open
280 esophageal adenocarcinomas that underwent primary surgical resection or resection after neoadjuvant therapy were analyzed by mRNA-in-situ-hybridization (RNAscope®) and by immunohistochemistry (TUBB3 rabbit monoclonal antibod…
View article: Somatic BRCA1‑associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma
Somatic BRCA1‑associated protein 1 (BAP1) loss is an early and rare event in esophageal adenocarcinoma Open
Esophageal cancer is the eighth most common malignant tumor worldwide, and the number of incidences of esophageal adenocarcinoma is increasing in the Western world. Despite improvements in perioperative treatment, the overall survival rate…
View article: Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer
Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer Open
ERCC1-SNP in combination with mRNA ERCC1, DPYD, and ERBB2 from pretherapeutic endoscopic biopsies can predict minor response to chemoradiation, as a basis for individualized therapy of advanced esophageal cancer.
View article: MDM2 gene amplification in esophageal carcinoma
MDM2 gene amplification in esophageal carcinoma Open
Esophageal cancer (EC) is one of the most common malignancies diagnosed in the Western world with an increasing incidence noted for esophageal adenocarcinoma (EAC). Despite improvements in staging, surgical procedures and postoperative tre…
View article: The Barrett‐associated variants at <i><scp>GDF</scp>7</i> and <i><scp>TBX</scp>5</i> also increase esophageal adenocarcinoma risk
The Barrett‐associated variants at <i><span>GDF</span>7</i> and <i><span>TBX</span>5</i> also increase esophageal adenocarcinoma risk Open
Barrett's esophagus ( BE ) and esophageal adenocarcinoma ( EAC ) represent two stages within the esophagitis‐metaplasia‐dysplasia‐adenocarcinoma sequence. Previously genetic risk factors have been identified that confer risk to BE and EAC …
View article: Supportive evidence for <i><scp>FOXP</scp>1</i>,<i><scp>BARX</scp>1</i>, and <i><scp>FOXF</scp>1</i> as genetic risk loci for the development of esophageal adenocarcinoma
Supportive evidence for <i><span>FOXP</span>1</i>,<i><span>BARX</span>1</i>, and <i><span>FOXF</span>1</i> as genetic risk loci for the development of esophageal adenocarcinoma Open
The Barrett's and Esophageal Adenocarcinoma Consortium ( BEACON ) recently performed a genome‐wide association study ( GWAS ) on esophageal adenocarcinoma ( EAC ) and Barrett's esophagus. They identified genome‐wide significant association…
View article: Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.
Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment. Open
Patients with advanced esophageal cancer (T3-4, N) have a poor prognosis. Chemoradiation or chemotherapy before esophagectomy with adequate lymphadenectomy is the standard treatment for patients with resectable advanced esophageal carcinom…
View article: Prä-operativer Status der körperlichen Leistungsfähigkeit von Patienten mit Magen- oder Ösophaguskarzinom
Prä-operativer Status der körperlichen Leistungsfähigkeit von Patienten mit Magen- oder Ösophaguskarzinom Open
Einleitung: Körperliche Aktivität stellt für Patienten mit einer Tumorerkrankung eine Möglichkeit dar, krankheitsbedingte Symptome sowie medizinische Nebenwirkungen zu verringern und die Lebensqualität zu steigern. Für Patienten mit Magen-…